Immunotherapy of cytomegalovirus infection after stem-cell transplantation: a new option?
Einsele
Hermann
H
Department of Haematology/Oncology, and Institute of Medical Virology and Epidemiology of Viral Diseases, University Hospital of Tübingen, 72076, Tübingen, Germany. hermann.einsele@med.uni-tuebingen.de
Hamprecht
Klaus
K
D000998:Antiviral Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D003587:Cytomegalovirus / Q000187:drug effects; D003586:Cytomegalovirus Infections / Q000188:drug therapy / Q000628:therapy*; D015774:Ganciclovir / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D016867:Immunocompromised Host / Q000276:immunology; D007167:Immunotherapy / Q000379:methods*; D011183:Postoperative Complications / Q000188:drug therapy / Q000628:therapy*; D033581:Stem Cell Transplantation; D013601:T-Lymphocytes / Q000276:immunology / Q000637:transplantation
D000998:Antiviral Agents; D015774:Ganciclovir